TempraMed Reports Record Sales Exceeding Full-Year 2025 Revenue

TempraMed Technologies Ltd., a medical-technology innovator based in Ontario, has reported record-breaking sales figures for July 2026, with the company achieving approximately US$522,000 in sales, the highest monthly sales in its history. August 2026 saw the company's second-highest monthly sales, reaching approximately US$403,000. These strong sales figures have already propelled the company's year-to-date sales to approximately US$2.07 million, surpassing the total sales for the full 2025 fiscal year, which was approximately US$1.8 million.

These results reflect growing market demand for their products and the early impact of their strategy to expand beyond direct-to-consumer sales into institutional, pharmacy, distributor, and healthcare-system channels, added Nagar.

The company believes its growth is supported by several key drivers, including increased awareness of medication temperature exposure, broader adoption of temperature-sensitive injectable therapies such as insulin and GLP-1 medications, expanding product availability through healthcare and pharmacy channels, and the company's continued transition toward a more diversified B2B and institutional commercial model.

TempraMed's management expects these trends to remain important drivers of the company's long-term growth strategy as it continues to expand access to its product portfolio across North America, Israel, Europe, Latin America, the Middle East, and other target markets.

For the eight-month period ended August 31, 2026, TempraMed recorded approximately US$2.07 million in sales, already exceeding the Company's total sales for the full 2025 fiscal year of approximately US$1.8 million.

The company's preliminary unaudited financial information indicates that third-quarter 2026 sales are expected to be significantly stronger than the third-quarter 2025 sales, reflecting continued commercial momentum across TempraMed's growing portfolio of medication temperature-protection products and expanding distribution channels.

For the eight-month period ended August 31, 2026, TempraMed recorded approximately US$2.07 million in sales, already exceeding the Company's total sales for the full 2025 fiscal year of approximately US$1.8 million.

The company's preliminary unaudited financial information indicates that third-quarter 2026 sales are expected to be significantly stronger than the third-quarter 2025 sales, reflecting continued commercial momentum across TempraMed's growing portfolio of medication temperature-protection products and expanding distribution channels.

TempraMed Technologies Ltd. is a global medical-device company with a portfolio of innovative, temperature-controlled medication-storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered thermal-insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™.